SCHEMBL6407314

SCHEMBL6407314

CCOC(=O)c1[nH]c(/C=C2\C(=O)Nc3ccc(OC)cc32)c(CCC(=O)O)c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.61
FGFR1 P11362 15/20 0.61
PDGFRB P09619 14/20 0.61
SRC P12931 2/20 0.55
EGFR P00533 4/20 0.53
FLT3 P36888 4/20 0.52
FLT4 P35916 2/20 0.52
KIT P10721 1/20 0.52
RET P07949 3/20 0.52
AURKA O14965 3/20 0.51
AURKB Q96GD4 3/20 0.50
FLT1 P17948 2/20 0.50
MAP4K2 Q12851 2/20 0.50
STK3 Q13188 2/20 0.50
AKT2 P31751 1/20 0.50
GAK O14976 1/20 0.50
RPS6KA5 O75582 1/20 0.50
RPS6KA4 O75676 1/20 0.50
LATS1 O95835 1/20 0.50
CSNK2A2 P19784 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407319 1.00 KDR (0.61) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6404732 0.93 KDR (0.71) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6404735 0.93 KDR (0.71) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6405120 0.91 KDR (0.65) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6405124 0.91 KDR (0.65) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6406975 0.89 FGFR1 (0.69) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6406978 0.89 FGFR1 (0.69) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6389700 0.86 FGFR1 (0.67) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6389704 0.86 FGFR1 (0.67) KDRFGFR1PDGFRBSRCEGFR
SCHEMBL6396424 0.85 FGFR1 (0.71) KDRFGFR1PDGFRBSRCEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 US disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 KDR 1617/4885FGFR1 2701/4885PDGFRB 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.